Disulfiram‐Induced Hepatotoxicity in a Patient With Alcohol Use Disorder: A Case Report Authors: Sonam Wangchuk, Bikram Chhetri, Jiann Lin Loo Published: 2026 ABSTRACT ABSTRACTDisulfiram can cause severe and potentially fatal hepatotoxicity, particularly in patients with preexisting liver disease. In Bhutan, where alcohol‐related liver disease represents a major public health burden and pharmacological options for relapse prevention remain limited, careful patient selection, hepatic assessment, and early monitoring are essential prior to initiating disulfiram therapy. Introduction Alcohol use disorder is a leading cause of preventable morbidity and mortality worldwide, and pharmacological relapse prevention forms a cornerstone of long‐term management. According to current guidelines, naltrexone and acamprosate are recommended as first‐line agents, while disulfiram is reserved as a second‐line option for alcohol use disorder [1, 2]. Disulfiram is an Antabuse which inhibits the aldehyde dehydrogenase enzyme, producing an aversive reaction upon alcohol ingestion. It can be an effective option in patients where the first‐line agents are contraindicated, ineffective, not tolerated, or in settings where the first‐line agents are not available [1, 2]. Although generally well tolerated, disulfiram carries a recognized risk of idiosyncratic hepatotoxicity, with an estimated incidence of approximately 1 in 30,000 patients/year [3, 4]. The clinical presentation ranges from asymptomatic transaminase elevation to fulminant hepatic failure, and most cases occur within the first 2–12 weeks of treatment [3, 4, 5]. The mechanism is thought to involve the accumulation of toxic metabolites—particularly diethyldithiocarbamate and carbon disulfide—leading to oxidative stress, mitochondrial dysfunction, and hepatocellular injury [5, 6]. Preexisting liver disease, as is common in patients with alcohol use disorder, may heighten this vulnerability [6]. In Bhutan, disulfiram remains the only pharmacological agent for relapse prevention routinely available in clinical practice, making its safe use particularly important. We report a case of disulfiram‐induced acute liver injury superimposed on alcohol‐related liver disease and highlight the best‐practice principles of patient selection, pretreatment assessment, and monitoring that may prevent similar adverse outcomes. Case History/Examination A 55‐year‐old woman with a medical history of type 2 diabetes mellitus and hypertension was admitted to the psychiatry ward at Jigme Dorji Wangchuck National Referral Hospital for alcohol detoxification. She had been consuming alcohol heavily for more than 5 years, meeting criteria for severe alcohol use disorder as per DSM‐5‐TR, with an estimated intake of 20–30 units per day. There was no history of depression, anxiety, or psychotic symptoms, and no prior episodes of hematemesis, melena, confusion, or seizures. The physical examinations were unremarkable. Baseline liver function tests on admission demonstrated elevated AST at 110 IU/L (reference: 5–46), ALT at 67 IU/L (reference: 5–49), alkaline phosphatase at 199 IU/L (reference: 35–104), and a markedly elevated gamma‐glutamyl transferase (GGT) at 1457 IU/L (reference: 5–32). Total bilirubin was mildly elevated at 1.28 mg/dL (reference: 0.00–1.20), with an INR of 1.29 (reference: 0.80–1.20). These findings were consistent with underlying alcohol‐related liver disease. Following completion of a 1‐week supervised detoxification program, a long‐term relapse‐prevention plan incorporating disulfiram 250 mg once daily was initiated, with supervised administration by her son. The elevated baseline liver enzymes were recognized prior to treatment initiation. However, the patient had no clinical evidence of hepatic decompensation, significant hyperbilirubinemia, ascites, encephalopathy, or marked impairment of synthetic liver function. Given the substantial risk associated with continued alcohol consumption and the absence of alternative relapse‐prevention pharmacotherapies such as naltrexone or acamprosate in Bhutan, a risk–benefit assessment was undertaken, and disulfiram was initiated with planned family‐supervised administration and clinical monitoring. Approximately 1 month after discharge, the patient re‐presented to the medical department with a 1‐week history of epigastric and right hypochondriac pain, nausea, a single episode of vomiting, progressive lethargy, and disturbed sleep–wake cycle. Family members reported increasing daytime somnolence, sleep reversal, and new‐onset yellowish discoloration of eye and skin with dark urine. There was no history of fever, pruritus, gastrointestinal bleeding, seizures, or ingestion of herbal or traditional medications. She remained abstinent from alcohol during the intervening period, as confirmed by both the patient and reliable family members. Breath alcohol analysis showed an alcohol level of zero; however, a blood alcohol level was not obtained. On examination, the patient was conscious (Glasgow Coma Scale 15/15) and fully oriented to time, place, and person. She was afebrile, icteric, and well hydrated, with no pallor or pedal edema. Neurological examination revealed bilateral asterixis (flapping tremor). Vital signs were stable with a blood pressure of 157/88 mmHg, pulse rate of 78 beats/min, respiratory rate of 16 breaths/min, and oxygen saturation of 94% on room air. Abdominal examination revealed right hypochondriac tenderness with hepatomegaly; the liver span was approximately 20 cm, with a smooth but tender, rounded edge. There was no clinical evidence of splenomegaly or ascites. Cardiovascular and respiratory examinations were unremarkable. Diagnosis/Differential Diagnosis Following systematic exclusion of viral hepatitis, obstructive, metabolic, and autoimmune causes, and given the clear temporal relationship between disulfiram initiation and onset of hepatic injury in a patient confirmed to be abstinent from alcohol, a diagnosis of disulfiram‐induced drug‐induced liver injury (DILI) presenting as acute liver failure on a background of alcohol‐related liver disease was established. The Roussel Uclaf Causality Assessment Method (RUCAM) yielded a score of 7, consistent with a probable causal relationship [7, 8], supporting disulfiram as the offending agent. Investigations Liver function tests revealed markedly elevated transaminases: AST 1067 IU/L and ALT 942 IU/L, with total bilirubin 2.98 mg/dL, direct bilirubin 1.62 mg/dL, and INR 1.39. GGT had declined to 414 IU/L from its admission baseline. The Maddrey's Discriminant Function was calculated at 42, indicating severe hepatitis with a high short‐term mortality risk. The hepatic encephalopathy was graded as Grade II based on clinical features. Hepatitis B surface antigen, hepatitis C antibody, HIV, and TPHA were all negative. Thyroid, renal, and electrolyte profiles were within normal limits. Fasting blood glucose was elevated at 254 mg/dL in the context of known diabetes. Amylase (156 U/L) and lipase (234.9 U/L) were mildly elevated without clinical features of pancreatitis. Alpha‐fetoprotein was borderline at 5.85 IU/mL. Albumin was mildly reduced at 3.42 g/dL. Autoimmune liver screen (ANA, anti‐smooth muscle antibody) and ceruloplasmin were not tested, representing a limitation; however, the clinical context and temporal relationship made autoimmune or metabolic etiology unlikely. Abdominal ultrasound demonstrated hepatomegaly of the left lobe (11 cm) with coarse echotexture and a contracted gallbladder. No focal hepatic lesions, biliary dilatation, ascites, or splenomegaly were identified. Treatment and Outcome Disulfiram was discontinued upon admission. The patient was managed with intravenous N‐acetylcysteine as per the standard non‐paracetamol acute liver failure protocol (150 mg/kg over 1 h, followed by 50 mg/kg over 4 h and 100 mg/kg over 16 h in 5% dextrose), along with lactulose for hepatic encephalopathy, thiamine supplementation, intravenous fluids, and other supportive care. Comorbidities were managed with insulin and antihypertensive therapy. No corticosteroids were administered given the DILI etiology and absent clinical features of autoimmune overlap. The patient was admitted for 9 days and demonstrated gradual clinical and biochemical improvement throughout. Jaundice and encephalopathy resolved progressively, and transaminases trended downward (Table 1). She was discharged in stable condition on Day 9. TABLE 1Serial liver function test results from baseline admission through 4‐month follow‐up, with clinical milestones.ParameterReference rangeBaseline (admission)Week 0 (disulfiram started/discharged psych)Week 4 (Day 0: Admission medical ward; disulfiram stopped)Day 7Day 9: Discharged medical wardMonth 2 (follow‐up 1)Month 3 (follow‐up 2)Month 4 (follow‐up 3)Clinical milestoneAdmissionDisulfiram started/discharged (psych)Admitted medical ward; disulfiram stopped, treatment startedDischarged (medical ward)Follow‐upFollow‐upFollow‐upAST (IU/L)5–46110↑ a —1067↑389↑170↑453025ALT (IU/L)5–4967↑ a —942↑554↑252↑50↑2416Alkaline phosphatase (IU/L)35–104199↑—196↑168↑150↑143↑ 133↑ 130↑ Total bilirubin (mg/dL)0.00–1.201.28↑—2.98↑2.20↑1.41↑1.39↑ 1.38↑ 0.95Direct bilirubin (mg/dL)0.00–0.400.55↑—1.62↑1.46↑0.87↑0.64↑ 0.54↑ 0.19Indirect bilirubin (mg/dL)0.20–0.800.73—1.36↑0.740.700.650.650.64GGT (IU/L)5–321457↑—414↑————80↑INR< 1.21.29↑—1.39↑1.191.08———Albumin (g/dL)3.50–5.20——3.42↓————3.80 Note: ↑, above reference range; ↓, below reference range; —, not recorded. Disulfiram was started at Week 0 and discontinued at Week 4 (Day 0) upon admission to the Medical Ward.Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase; INR, international normalized ratio. a Baseline values on admission prior to disulfiram initiation. Serial liver function test results from baseline admission through 4‐month follow‐up, with clinical milestones. Note: ↑, above reference range; ↓, below reference range; —, not recorded. Disulfiram was started at Week 0 and discontinued at Week 4 (Day 0) upon admission to the Medical Ward. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase; INR, international normalized ratio. Baseline values on admission prior to disulfiram initiation. Conclusion and Result At 4‐month follow‐up, after monthly outpatient reviews, the patient remained clinically stable and continued regular psychiatric follow‐up. She maintained abstinence from alcohol based on self‐report and corroboration from family members. No further episodes of jaundice, abdominal pain, encephalopathy, or hospital admission occurred during the follow‐up period. Liver function tests had largely normalized, with AST 25 IU/L, ALT 16 IU/L, total bilirubin 0.95 mg/dL, and albumin 3.80 g/dL. She remained functionally independent, adhered well to psychosocial relapse‐prevention interventions, and had no physical complaints or signs of ongoing liver disease. This case demonstrates that disulfiram‐induced DILI can produce life‐threatening acute liver failure, even at standard doses and within the first month of therapy, particularly when initiated in patients with preexisting alcohol‐related liver disease. Despite a Maddrey's Discriminant Function of 42 and Grade II hepatic encephalopathy—indices that conventionally confer high short‐term mortality—full clinical and biochemical recovery was achieved through prompt drug discontinuation, N‐acetylcysteine therapy, and supportive management. Early recognition was decisive. In resource‐limited settings where pharmacological alternatives remain unavailable, these safeguards are not merely best practice—they are essential. Discussion This case of disulfiram‐induced DILI illustrates three clinically important themes: the risk of severe hepatotoxicity in a patient with preexisting alcohol‐related liver disease; the diagnostic challenge of distinguishing DILI from spontaneous hepatic decompensation; and the feasibility of full recovery when the offending agent is identified and withdrawn promptly. Together, these themes converge on a clear best‐practice message regarding patient selection, monitoring, and institutional preparedness. Patient Selection and Risk Stratification A central concern in this case was the initiation of disulfiram in a patient with demonstrably abnormal baseline liver function. The baseline GGT of 1457 IU/L—nearly 46 times the upper limit of normal—reflected substantial hepatic inflammation, even in the absence of synthetic dysfunction at that point. While no universally accepted threshold formally contraindicates disulfiram, current evidence advises extreme caution or avoidance in patients with active hepatic inflammation or impaired synthetic function [4, 5]. The American Psychiatry Association guidelines further stipulate that disulfiram should be reserved for patients without contraindications and who can understand its risks [1]. Pretreatment evaluation should therefore include a full liver panel encompassing transaminases, bilirubin, GGT, albumin, and INR, with careful risk–benefit deliberation before initiation in patients with alcohol‐related liver disease. Diagnosis of DILI in the Context of Chronic Liver Disease Establishing a DILI diagnosis when underlying hepatic disease is present requires systematic exclusion of competing causes. In this case, negative viral serology, absence of biliary obstruction on imaging, confirmed alcohol abstinence, and a clear temporal relationship between drug initiation and hepatic injury collectively supported the diagnosis. The RUCAM—a validated, quantitative, and hepatotoxicity‐specific causality instrument—yielded a probable causal relationship [7, 8], consistent with published case series implicating disulfiram [3, 5, 6]. Confirmed abstinence was the critical diagnostic anchor: without it, alcohol relapse could not have been confidently excluded as the precipitant. Autoimmune and selected metabolic investigations, including antinuclear antibody, anti‐smooth muscle antibody, and ceruloplasmin, were not performed, which represents a limitation of this report. However, the temporal association with disulfiram initiation, exclusion of viral and obstructive causes, documented alcohol abstinence, and a probable RUCAM score strongly supported disulfiram‐induced DILI, making alternative etiologies less likely. Severity and Management A Maddrey's Discriminant Function of 42, combined with Grade II hepatic encephalopathy, placed this patient in a high short‐term mortality category conventionally associated with greater than 50% 28‐day mortality in alcoholic hepatitis [9]. That full recovery was nonetheless achieved underscores the importance of early identification and drug withdrawal. Intravenous N‐acetylcysteine—a glutathione precursor that attenuates oxidative hepatocellular injury—was a key therapeutic component; it has demonstrated improved transplant‐free survival in non‐paracetamol‐related acute liver failure, including DILI [10, 11]. Monitoring and Institutional Practice Published guidance recommends liver function testing at baseline, fortnightly for the first 2 months, and then monthly to 6 months—the period during which the majority of cases occur [4, 12]. Patients and caregivers should be counseled to promptly report early symptoms such as jaundice, fatigue, and abdominal pain, and monitoring practices should be further strengthened. This case also highlights the importance of closer interdisciplinary collaboration and consultation between psychiatry and internal medicine in the management of patients with coexisting alcohol use disorder and hepatic impairment. Access to Alternative Agents At JDWNRH, alcohol use disorder accounts for up to 12% of psychiatry outpatient attendances and 43.45% of inpatient admissions [13], and alcohol‐related liver disease is among the leading causes of national mortality [14]. In this context, disulfiram's status as the sole available relapse‐prevention agent creates a therapeutic dilemma: the population most in need of treatment is also the most vulnerable to its principal serious adverse effect. Expanding access to naltrexone and acamprosate—recommended as first‐line agents by both APA and SAMHSA guidelines [1, 12]—would enable safer, more individually tailored management and reduce reliance on disulfiram in patients with hepatic comorbidity. Author Contributions Sonam Wangchuk: conceptualization, investigation, methodology, software, data curation, writing – original draft, writing – review and editing, formal analysis, validation, project administration, resources, visualization. Bikram Chhetri: supervision, writing – review and editing, formal analysis, methodology, data curation, conceptualization, validation. Jiann Lin Loo: writing – review and editing, supervision, data curation, conceptualization, validation. Funding The authors have nothing to report. Ethics Statement Ethical approval was granted by the Institutional Review Board of Khesar Gyalpo University of Medical Sciences of Bhutan (KGUMSB). Necessary administrative approvals were obtained prior to publication. Consent Written informed consent was obtained from the patient for publication of this case report and any accompanying data. Conflicts of Interest The authors declare no conflicts of interest.